Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025
Cryoport (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, has scheduled its Q2 2025 earnings release for August 5, 2025 after U.S. markets close.
The company will release a document titled "Cryoport Second Quarter 2025 in Review" at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET. Management will address questions from the investment community regarding the reported results, accompanied by a slide deck presentation.
The earnings call can be accessed via phone (U.S.: 1-800-717-1738, International: 1-646-307-1865) or webcast through the company's investor relations website. A replay will be available until August 12, 2025.
Cryoport (NASDAQ:CYRX), leader globale nelle soluzioni di supply chain a temperatura controllata per le scienze della vita, ha programmato la pubblicazione dei risultati del secondo trimestre 2025 per il 5 agosto 2025 dopo la chiusura dei mercati statunitensi.
L'azienda rilascerà un documento intitolato "Cryoport Secondo Trimestre 2025 in Rassegna" alle 16:05 ET, seguito da una conferenza Q&A alle 17:00 ET. Il management risponderà alle domande della comunità degli investitori riguardo ai risultati riportati, accompagnato da una presentazione con slide.
La chiamata per i risultati potrà essere seguita telefonicamente (USA: 1-800-717-1738, Internazionale: 1-646-307-1865) oppure in webcast tramite il sito web delle relazioni con gli investitori dell’azienda. Una replica sarà disponibile fino al 12 agosto 2025.
Cryoport (NASDAQ:CYRX), líder global en soluciones de cadena de suministro con control de temperatura para las ciencias de la vida, ha programado la publicación de sus resultados del segundo trimestre de 2025 para el 5 de agosto de 2025 después del cierre de los mercados estadounidenses.
La compañía publicará un documento titulado "Cryoport Segundo Trimestre 2025 en Revisión" a las 4:05 p.m. ET, seguido de una llamada de preguntas y respuestas a las 5:00 p.m. ET. La dirección responderá a las preguntas de la comunidad inversora sobre los resultados reportados, acompañado de una presentación con diapositivas.
La llamada de resultados podrá ser accedida por teléfono (EE.UU.: 1-800-717-1738, Internacional: 1-646-307-1865) o por webcast a través del sitio web de relaciones con inversores de la empresa. Una repetición estará disponible hasta el 12 de agosto de 2025.
Cryoport (NASDAQ:CYRX)는 생명 과학 분야를 위한 온도 제어 공급망 솔루션의 글로벌 선두주자로서, 2025년 8월 5일 미국 시장 마감 후 2025년 2분기 실적 발표를 예정하고 있습니다.
회사는 오후 4시 5분(동부시간)에 "Cryoport 2025년 2분기 검토"라는 문서를 발표하고, 오후 5시(동부시간)에는 질의응답 컨퍼런스 콜을 진행할 예정입니다. 경영진은 보고된 실적에 대해 투자자들의 질문에 답변하며, 슬라이드 자료도 함께 제공됩니다.
실적 발표 콜은 전화(미국: 1-800-717-1738, 국제: 1-646-307-1865) 또는 회사 투자자 관계 웹사이트를 통한 웹캐스트로 참여할 수 있습니다. 녹음본은 2025년 8월 12일까지 제공됩니다.
Cryoport (NASDAQ:CYRX), leader mondial des solutions de chaîne d'approvisionnement à température contrôlée pour les sciences de la vie, a programmé la publication de ses résultats du deuxième trimestre 2025 pour le 5 août 2025 après la clôture des marchés américains.
La société publiera un document intitulé "Cryoport Revue du deuxième trimestre 2025" à 16h05 ET, suivi d'une conférence téléphonique de questions-réponses à 17h00 ET. La direction répondra aux questions de la communauté des investisseurs concernant les résultats annoncés, accompagnée d'une présentation en diaporama.
La conférence téléphonique pourra être suivie par téléphone (États-Unis : 1-800-717-1738, International : 1-646-307-1865) ou en webcast via le site des relations investisseurs de l'entreprise. Une rediffusion sera disponible jusqu'au 12 août 2025.
Cryoport (NASDAQ:CYRX), ein weltweit führendes Unternehmen für temperaturkontrollierte Lieferkettenlösungen im Bereich Life Sciences, hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 für den 5. August 2025 nach Börsenschluss in den USA geplant.
Das Unternehmen wird um 16:05 Uhr ET ein Dokument mit dem Titel "Cryoport Rückblick auf das zweite Quartal 2025" veröffentlichen, gefolgt von einer Fragerunde um 17:00 Uhr ET. Das Management wird Fragen der Investoren zu den berichteten Ergebnissen beantworten, begleitet von einer Präsentation mit Folien.
Der Ergebnisanruf kann telefonisch (USA: 1-800-717-1738, international: 1-646-307-1865) oder per Webcast über die Investor-Relations-Website des Unternehmens verfolgt werden. Eine Aufzeichnung ist bis zum 12. August 2025 verfügbar.
- None.
- None.
In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Tuesday, August 5, 2025. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: | Tuesday, August 5, 2025 |
Time: | 5:00 p.m. ET |
Dial-in numbers: | 1-800-717-1738 ( |
Confirmation code: | Request the "Cryoport Call" or Conference ID: 1197564 |
Live webcast: | 'Investor Relations' section at www.cryoportinc.com or click here.
Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software. |
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until August 12, 2025. To access the replay, dial 1-844-512-2921 (
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Headquartered in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-second-quarter-2025-financial-results-on-august-5-2025-302510338.html
SOURCE Cryoport, Inc.